Cargando…

Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis

BACKGROUND: D-dimer has been widely used for the diagnosis and prognosis of ovarian cancer, but there is still controversy on its prediction value of ovarian cancer. OBJECTIVES: To explore the clinical significance of plasma D-dimer level on ovarian cancer systematically. METHODS: Using PubMed, Coch...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiacong, Fu, Ziyi, Liu, Guangquan, Xu, Pengfei, Xu, Juan, Jia, Xuemei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484191/
https://www.ncbi.nlm.nih.gov/pubmed/28640083
http://dx.doi.org/10.1097/MD.0000000000007062
_version_ 1783245833132572672
author Wu, Jiacong
Fu, Ziyi
Liu, Guangquan
Xu, Pengfei
Xu, Juan
Jia, Xuemei
author_facet Wu, Jiacong
Fu, Ziyi
Liu, Guangquan
Xu, Pengfei
Xu, Juan
Jia, Xuemei
author_sort Wu, Jiacong
collection PubMed
description BACKGROUND: D-dimer has been widely used for the diagnosis and prognosis of ovarian cancer, but there is still controversy on its prediction value of ovarian cancer. OBJECTIVES: To explore the clinical significance of plasma D-dimer level on ovarian cancer systematically. METHODS: Using PubMed, Cochrane Library, and Web of Science libraries, all the relevant studies for the diagnostic and prognostic value of plasma D-dimer for ovarian cancer and the relationship between elevated D-dimer level and venous thromboembolism (VTE) risk of ovarian cancer were searched till May 30, 2016. Standardized mean difference (SMD), odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI) were appropriately pooled. RESULTS: A total of 15 eligible studies involving a total of 1437 cancer patients were included. No significant association was found between high D-dimer level and overall survival of patients with ovarian cancer (HR 1.32, 95% CI: 0.90–1.95, P  =  .044). However, subgroup analysis indicated that the sample sizes could explain the heterogeneity between studies. And elevated D-dimer could predict increased risk of mortality when the sample sizes were >100 (HR 1.800, 95% CI: 1.283–2.523, P  =  .845). Besides, plasma D-dimer level was significantly higher in malignant ovarian cancer patients compared with benign controls (SMD 0.774, 95% CI: 0.597–0.951, P  =  .39), higher in advanced ovarian cancer patients (International Federation of Gynecology and Obstetrics [FIGO] classification III and IV) than in early stage ovarian cancer patients (FIGO classification I and II, SMD 0.611, 95% CI: 0.373–0.849, P  =  .442). And high D-dimer level indicated high VTE risk (OR 4.068, 95% CI: 2.423–6.829, P  =  .629) of ovarian cancer patients. CONCLUSION: The plasma D-dimer level in ovarian cancer patients can predict the changes that correlated with disease progression and the VTE risk. But its predictive value for the prognosis of ovarian cancer was significantly dependent on the sample sizes. More well-designed studies with large sample sizes are needed to validate and update the findings of present study.
format Online
Article
Text
id pubmed-5484191
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54841912017-07-06 Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis Wu, Jiacong Fu, Ziyi Liu, Guangquan Xu, Pengfei Xu, Juan Jia, Xuemei Medicine (Baltimore) 4100 BACKGROUND: D-dimer has been widely used for the diagnosis and prognosis of ovarian cancer, but there is still controversy on its prediction value of ovarian cancer. OBJECTIVES: To explore the clinical significance of plasma D-dimer level on ovarian cancer systematically. METHODS: Using PubMed, Cochrane Library, and Web of Science libraries, all the relevant studies for the diagnostic and prognostic value of plasma D-dimer for ovarian cancer and the relationship between elevated D-dimer level and venous thromboembolism (VTE) risk of ovarian cancer were searched till May 30, 2016. Standardized mean difference (SMD), odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI) were appropriately pooled. RESULTS: A total of 15 eligible studies involving a total of 1437 cancer patients were included. No significant association was found between high D-dimer level and overall survival of patients with ovarian cancer (HR 1.32, 95% CI: 0.90–1.95, P  =  .044). However, subgroup analysis indicated that the sample sizes could explain the heterogeneity between studies. And elevated D-dimer could predict increased risk of mortality when the sample sizes were >100 (HR 1.800, 95% CI: 1.283–2.523, P  =  .845). Besides, plasma D-dimer level was significantly higher in malignant ovarian cancer patients compared with benign controls (SMD 0.774, 95% CI: 0.597–0.951, P  =  .39), higher in advanced ovarian cancer patients (International Federation of Gynecology and Obstetrics [FIGO] classification III and IV) than in early stage ovarian cancer patients (FIGO classification I and II, SMD 0.611, 95% CI: 0.373–0.849, P  =  .442). And high D-dimer level indicated high VTE risk (OR 4.068, 95% CI: 2.423–6.829, P  =  .629) of ovarian cancer patients. CONCLUSION: The plasma D-dimer level in ovarian cancer patients can predict the changes that correlated with disease progression and the VTE risk. But its predictive value for the prognosis of ovarian cancer was significantly dependent on the sample sizes. More well-designed studies with large sample sizes are needed to validate and update the findings of present study. Wolters Kluwer Health 2017-06-23 /pmc/articles/PMC5484191/ /pubmed/28640083 http://dx.doi.org/10.1097/MD.0000000000007062 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4100
Wu, Jiacong
Fu, Ziyi
Liu, Guangquan
Xu, Pengfei
Xu, Juan
Jia, Xuemei
Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis
title Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis
title_full Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis
title_fullStr Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis
title_full_unstemmed Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis
title_short Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis
title_sort clinical significance of plasma d-dimer in ovarian cancer: a meta-analysis
topic 4100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484191/
https://www.ncbi.nlm.nih.gov/pubmed/28640083
http://dx.doi.org/10.1097/MD.0000000000007062
work_keys_str_mv AT wujiacong clinicalsignificanceofplasmaddimerinovariancancerametaanalysis
AT fuziyi clinicalsignificanceofplasmaddimerinovariancancerametaanalysis
AT liuguangquan clinicalsignificanceofplasmaddimerinovariancancerametaanalysis
AT xupengfei clinicalsignificanceofplasmaddimerinovariancancerametaanalysis
AT xujuan clinicalsignificanceofplasmaddimerinovariancancerametaanalysis
AT jiaxuemei clinicalsignificanceofplasmaddimerinovariancancerametaanalysis